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ABSTRACT
HIV-specific cytotoxic T lymphocytes (CTLs) play an important role in the immune response to HIV infec-
tion. Long-term nonprogressors (LTNPs) or slow progressors (SPs) in HIV infection may make qualitatively
different CTL responses compared to those generated by seropositive individuals who progress to disease at
a faster rate. The class I molecule HLA-B 57 has been identified as one restriction element overrepresented
in SP groups studied, and, together with the closely related molecule HLA-B*58, occurs commonly in ethnic
groups where HIV is most prevalent. In this study, we have identified five new HLA-B*57-restricted CTL epi-
topes recognized by SP donors, one of which is also HLA-B*5801 restricted. These HLA-B*57-restricted re-
sponses represent the dominant HIV-specific CTL response in each of the SP donors tested. These and other
such epitopes may be an important component in future vaccine design.
INTRODUCTION
Human
immunodeficiency viRus-specific cytotoxic T lym-
phocytes (CTLs) are believed to play an important role in
the immune response to HIV infection.1 The appearance of
HIV-specific CTLs in the blood of individuals at or prior to se-
roconversion closely corresponds to the disappearance of
viremia,2 and high levels of CTLs have been associated with
the maintenance of the disease-free phase of infection.3
However, the great majority of HIV-infected individuals gen-
erate a strong CTL response to the virus during the asympto-
matic phase of infection, and it is not possible to distinguish on
the basic of CTL precursor frequency at this stage between the
group who will progress to disease more rapidly, and those who
will not progress or who will progress more slowly (slow pro-
gressors: SPs).4
One hypothesis, to explain this paradox, would be that there
is a qualitative difference between the CTL responses shown
by SP donors and the progressors. We therefore identified a
group of SP donors, and focused on those HLA class I mole-
cules overrepresented in this group compared to a control group
of progressors, initially in order to identify and define CTL re-
sponses made through these restriction elements.
One such restriction element of potential interest is HLA-
B*57, since this and the closely related class I molecule HLA-
B*58 are extremely common in African populations. For ex-
ample, one of these two class I molecules is present in 43% of
Zimbabwean5 and 40% of Ugandan populations.53 In addition,
HLA-B*57 is the single class I molecule that has been identi-
fied as occurring more frequently than expected in a prelimi-
nary study of the well-studied Amsterdam long-term nonpro-
gressor (LTNP) cohort6 and also is a strong marker in a second
LTNP study.7 Convincing HLA associations are exceedingly
difficult to obtain,8 principally because of the large sample sizes
required, the very large number of comparisons made, and also
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because of inaccuracies in 12-37% of serological class I typ-
ing, compared to methods that employ sequence-specific
oligonucleotide primers now available9,10 (and M. Bunce, per-
sonal communication). The study by Kaslow et al.1 is the most
thorough to date, and HLA-B*57 was second to HLA-B*27 as
the marker most closely associated with nonprogression in both
cohorts studied.
Those CTL epitopes restricted by one or both of the HLA
class I molecules HLA-B*57 or -B*58, and that are also asso-
ciated with long-term nonprogression in HIV infection, might
therefore be important ultimately in vaccine development. A
previous study of CTL epitopes within the Nef protein11 noted
that one HLA-B*57-restricted epitope was equally well pre-
sented by HLA-B*58 (not subtyped).12 The possibility that the
five novel HLA-B57-restricted epitopes identified here in SP
donors are also "cross-restricted" by HLA-B*58 is explored.
One of the five appears to be equally presented by HLA-B*5801
targets to HLA-B*57 effector cells, and is shown to be recog-
nized also by HLA-B*5801 effectors on HLA-B*57 targets.
This study is designed to identify and define the CTL re-
sponses made by HLA-B*57- and HLA-B*58-positive donors
as an initial component of a long-term longitudinal analysis in
order to determine correlates of progression and nonprogres-
sion in HIV infection.
MATERIALS AND METHODS
Long-term slow progressor and progressor donors
Criteria for inclusion into the slow progressor (SP) study
group were as follows: HIV infected for 7 years or more, asymp-
tomatic, CD4 count in the normal range (above 400 ceMslpl),
and no history of antiretroviral therapy. Criteria for inclusion
into the progressor group were as follows: HIV infected less
than 5 years, CD4 count less than 400 cells/^il.
HLA class I tissue typing
HLA class I tissue typing was performed by polymerase
chain reaction (PCR), using sequence-specific primers.13'14
Identification of novel HLA-B57-restricted epitopes
and putative B5801 cross-restricted epitopes
Seropositive donors with HLA-B*57 and HLA-B*58 were
identified. Autologous B lymphoblastoid cell lines (BCLs) were
infected for 16 hr with recombinant vaccinia viruses express-
ing a panel of HIV-1 proteins. Overlapping 20-mer peptides
within the protein recognized were then tested for recognition.
Shorter peptides within the 20-mer recognized were then syn-
thesized, including 8- to 12-mers fitting the motif previously
described for HLA-B*5801.15 HLA restriction and cross-re-
striction was then established using BCLs matched through sin-
gle HLA class I molecules.
Having identified three novel HLA-B*57 epitopes that fitted
the HLA-B*5801 motif, further putative epitopes consistent
with this motif (alanine, valine, serine, or threonine at position
2; tryptophan or phenylalanine at the C-terminal position) were
identified from the Gag, Pol, and Nef amino acid sequences16
and synthesized.
Generation of cytotoxic T lymphocyte cultures
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from blood by Ficoll-Hypaque density gradient cen-
trifugation. CTL "bulk" cultures were generated according to
the protocol set out by Nixon et al.11 Briefly, one-fifth of
PBMCs were phytohemagglutinin (PHA) activated and
washed twice after 24 hr before being added back to the other
four-fifths. Cells were cultured in RPMI 1640 (Sigma, St.
Louis, MO) supplemented with antibiotics and 10% heat-in-
activated fetal calf serum (FCS) (Globepharm, Esher, UK). After
7 days, 10% Lymphocult T (Biotest, Solihull, UK) was added to
the medium. Peptide-specific lines were generated using irradi-
ated autologous peptide-pulsed Epstein-Barr virus (EBV)-trans-
formed B lymphoblastoid cell lines as weekly feeders.
Vaccinia viruses
Vaccinia viruses used to infect targets were recombinants en-
coding gpl20, Gag, Pol, Nef, and Tat of the HIV-1 BRU iso-
late, with the control vaccinia being a recombinant encoding
the influenza protein PB2. The vaccinia constructs were sup-
plied by the Medical Research Council AIDS Directed
Programme (MRC ADP).
Cytotoxic T lymphocyte assays
Target cells (autologous or HLA class I-matched BCLs) were
labeled with radioactive chromium and peptide pulsed for 1 hr
prior to the assay. A total of 5 X 103 targets was used per well.
Percent lysis was calculated according to the formula: 100 X
(E
— M)I(T
— M), where E is the chromium release from the su-
pernatant of wells containing targets and effectors, M is the re-
lease from wells containing targets and medium only, and T is
the release from wells containing targets and 5% Triton X.
Background lysis (MIT) was less than 30% in all assays. Assays
were harvested at 4-6 hr. Specific lysis was calculated by sub-
tracting the percent lysis of targets pulsed with test peptide or in-
fected with test vaccinia from the percent lysis of targets pulsed
with no peptide or infected with control vaccinia, respectively.
Peptides
Overlapping peptides 20 amino acids in length were supplied
by the MRC ADP. Shorter peptides 8-12 amino acids in length
were synthesized on an automated peptide synthesizer (Advanced
Chem Tech, Comberton, UK) using standard 9-fluorenylmethoxy-
carbonyl (Fmoc) chemistry. Thepurityofpeptides was established
by high-performance liquid chromatography (HPLC); they were
then weighed and dissolved in RPMI. Peptides that did not dis-
solve easily in RPMI were initially dissolved in dimethyl sulfox-
ide (DMSO) to a maximum concentrationof 1% DMSO at a pep-
tide concentration of 100 pM.
RESULTS
Ethnicity ofdonors within slow progressor and
progressor groups
Thirty of the 33 donors within the SP group were Caucasian;
the remaining 3 were Nigerian, Zimbabwean, and Thai. All 29
donors within the progressor group were Caucasian.IMMUNODOMINANT CTL EPITOPES IN HIV-I SLOW PROGRESSORS 1693
Frequency of HLA-B*57 in slow progressor and
progressor groups
HLA-B*57 was present in 9 of the 30 Caucasians in the SP
group studied (HLA-B*57-positive donors are listed in Table
1). Compared with the frequency of this class I molecule in the
2 of 29 Caucasian donors in the progressor group, HLA-B*57
is overrepresented in the SP group (odds ratio 5.79; 95% con-
fidence interval [CI] 26.23-1.28; p < 0.013, using 2X2V2,
not correcting for multiple comparisons). Not included in this
comparison were the tissue types of the three non-Caucasians
within the SP group, two of whom were HLA-B*57 positive,
and one of whom was HLA-B*5801 positive (donor 19M). For
comparison, the frequency of HLA-B*57 in the general popu-
lation of British Caucasians is 11%.5
Definition of a novel HLA-B''5801-restricted
epitope, TSTLQEQIGW
Bulk CTLs from donor 19M, a Zimbabwean, recognized an
epitope in p24*aﾫ within the 20-mer GSDIAGTTSTLQEQIG-
WMTN (Fig. la). The optimal peptide had the sequence TSTLQE-
QIGW (HIV-1 LAI Gag amino acid residues 250-260) (Fig. lb)
and was well recognized at concentrations of 10 nM by a peptide-
specific Une (Fig. lc). The HLA restriction of the response was
established as HLA-B*5801, but peptide-pulsed HLA-B*57 tar-
gets were also recognized by CTLs from this donor (Fig. Id).
Identification of an HLA-B*57-restricted response to
the peptide TSTLQEQIGW by two HLA-B*57-positive
slow progressors
Cytotoxic T lymphocytes from four HLA-B*57-positive SP
donors recognized this peptide TSTLQEQIGW bound to HLA-
B*57-matched targets (Table 2; and CTLs from donor 422, not
shown). This was the dominantresponse identifiedin donor422
(not shown) and one of several strong responses identified
donor 051. A peptide-specific line from donor 051 recognized
the peptide equally well when presented by HLA-B*57 targets
and HLA-B*5801 targets; but did not recognize the peptide on
HLA-B*5802 targets (Fig. 2a).
Identification offourfurther HLA-B57-restricted
epitopes in slow progressors
Bulk culture from donor 032 made a dominant response to
Gag-vaccinia-infected autologous targets (Fig. 3a), and the 20-
mer peptide within Gag best seen by these cells was p24.2, se-
quence VHQAISPRTLNAWVKVVEEK, HTV-1 LAI Gag
amino acid sequence residues 143-162 (not shown). Using the
HLA-B*5801 motif of serine, threonine, or alanine at position
2 and tryptophan or phenylalanine at position 917 (Table 3), the
predicted epitope sequence ISPRTLNAW (residues 147-155)
was synthesized and tested, and was well recognized (Fig. 3b).
Four other donors have made responses to this epitope (Table
2; and donor 949, not shown); in Nigerian donor 949 this was
the dominant response (not shown).
The dominant Gag response seen in bulk CTLs from donor
998 was to the 20-mer NAWVKVVEEKAFSPEVIPMF
(residues 153-172; not shown). Using the motif for HLA-
B*5801, the peptides FSPEVIPMF and KAFSPEVIPMF
(residues 162-172) were tested, and only the latter was well
recognized (Figs. 3c and 2b). This epitope was also well seen
by CTLs from other donors (Table 2).
Thepanelof 19 putative HLA-B*57-restrictedpeptide epitopes,
which was derived using the peptide motif for HLA-B*5801,17
was tested for recognition by bulk CTLs from several donors. The
Nef peptide GPGVRYPLTFGWCY (residues 130-143) was
strongly recognized by CTLs from four donors, and there was
recognition of another Gag peptide, QASQDVKNW (residues
309-317), by CTLs from two donors (Table 2).
Table 1. Ethnicity, HLA Class I A and B Types, Latest CD4 Count, and
Duration/Date of Infection of HLA-B57 and HLA-B5801 Donors Studied3
Donor/
ethnic group
HLA class I A*/
B* tissue type
CD4 count
(cells/pl)
Duration/date
ofinfection
(years/year
infected)
Slow progressors
031 (Caucasian)
032 (Caucasian)
051 (Caucasian)
058 (Caucasian)
422 (Caucasian)
998 (Caucasian)
220 (Caucasian)
824 (Caucasian)
IM (Caucasian)
19M (Zimbabwean)
20M (Thai)
949 (Nigerian)
Progressors
196 (Caucasian)
5M (Caucasian)
A*01/*02
A*01/*32
A*01/*24
A*28/*29
A*24/*31
A*01/*01
A*02/*02
A*01/*02
A*01/*02
A*ll/*30o2
A*02/*33
A*23/*33
A*03/*03
A*02/*03
B*51/*57
B*44/*57
B*44/*57
B*51/*57
B*27/*57
B*52/*57
B*35/*57
B*44/*57
B*07/*57
B*52/*5801
B*61/*57
B*45/*57
B*35/*57
B*07/*57
410
1190
620
520
1040
400
480
580
850
490
520
480
320
210
13/1983
13/1983
13/1983
11/1983
9/1987
7/1989
10/1986
12/1984
8/1988
7/1989
10/1987
7/1989
5/1991
6/1990
aDonor 058 died in 1994 from HIV-unrelated causes, and tissue typing of this donor was performed
using standard serological methods.1694 GOULDER ET AL.
Vaccinia-infected or peptide-pulsed targets
peptide concentration (log molar)
Peptide
? 30
19M targets
19C (HLA-B*5801)
AL (HLA-B*5801)
PH (HLA-B'57)
18C (HLA-B'57)
HR (HLA-B'13)
FIG. 1. (a) Recognition of Gag-vaccinia-infected and peptide-pulsed autologous targets by bulk CTLs from donor 19M (HLA
class I type: A*l 1/30.02 B*52/5801). Effector:target (E:T) ratio, 40:1; pl7.1-13, overlapping 15-mers spanning pl7*a* protein;
p24.1-22, overlapping 20-mers spanning p24ﾫﾰﾫ protein; p24.1-6, pool of six 20-mers p24.1-p24.6 inclusive; other pools desig-
nated likewise. The 20-mers recognized: p24.7 (sequence GHQAAMQMLKETINEEAAEW, HIV LAI positions 193-212) and
p24.11 (GSDIAGTTSTLQEQIGWMTN, positions 233-252). Lysis of vaccinia-influenza PB2 control subtracted (4.1%) and ly-
sis of targets pulsed with no peptide (1.2%) subtracted to calculate percent specific lysis, (b) Optimization of epitope within
p24.11, sequence GSDIAGTTSTLQEQIGWMTN. The 8-12-mers were assayed at 1 pM concentrations, the 20-mer assayed at
10 pM. Lysis of targets pulsed with no peptide (3.2%) subtracted, (c) Titration of optimal epitope, TSTLQEQIGW. Effectors,
peptide-specific line; E:T 12:1. Lysis of targets pulsed with no peptide (1.4%) subtracted, (d) Presentation of TSTLQEQIGW on
HLA-B57 and HLA-B5801 targets to HLA-B5801 effectors: 19M (HLA-A*11/30.02 B*52/5801). Bulk cultured lymphocytes,
E.T shown. Other HLA class I A and B types: 19C, A*l/30.02 B*8/5801; AL, A*3/24 B*18/5801; PH, A*28/29 B*51/57; 18C,
A*l/3 B*7/57; HR, A*30.01/- B*13/-.
Table 2. HLA-B*57-Restricted CTL Responses of Four Donors Tested for
Recognition of Five Novel Epitopes Described and One Previously Described3
Percent lysis of targets peptide pulsed with:
Donor No peptide 1SPRTLNAW KAFSPEVIPMF TSTLQEQIGW QASQDVKNW GPGVRYPLTFGWCY HTQGYFPDW
032
051
998
824
IM
2
12
12
7
-2
43
29
25
56
2
24
30
34
55
28
20
50
29
6
0
-6
54
25
7
2
0
67
53
44
38
11
26
10
8
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—•— HLA B57
—D— HLA B5801
M HLA 5802
-7 -6 -5
peptide concentration (log molar)
— — HLA B57
—Q— HLA B5801
-7 -6 -5
peptide concentration (log molar)
FIG. 2. (a) Presentation of TSTLQEQIGW by HLA-B*57, HLA-B*5801, and HLA-B*5802 targets to HLA-B*57-positive ef-
fectors: 051 (HLA-A*l/24 B*44/57). Peptide-specific line, E:T 5:1. Lysis of targets pulsed with no peptide (3.2%) subtracted,
(b) Presentation of KAFSPEVIPMF by HLA-B*57 and HLA-B*5801 targets. Effectors: 998 (HLA-A*1/- B*52/57), peptide-spe-
cific line, E:T 5:1. Lysis of targets pulsed with no peptide (6%) subtracted.
These four epitopes (ISPRTLNAW, KAFSPEVIPMF,
QASQDVKNW, and GPGVRYPLTFGWCY) were shown to
be HLA-B*57 restricted but not HLA-B*5801 cross-restricted
(data not shown), except at high peptide concentrations (Fig.
2b). ISPRTLNAW and KAFSPEVIPMF are found within 20-
to 22-mers (respectively, VHOAISPRTLNAWVKVVEEKAF
and NAWVKVVEEKAFSPEVIPMFSA1 that have previously
been shown to be HLA-B*57 restricted.18
Immunodominant cytotoxic T lymphocyte responses in
HLA-B*57- and HLA-B*5801-positive donors
The dominant HIV-specific CTL response in a donor was
defined by the peptide best recognized by "bulk" cultured lym-
phocytes on peptide-pulsed autologous targets. The three HLA-
B*57-restricted responses identified in donor 824 were the dom-
inant responses observed. The only response identified that was
O ftO
S. Z
S 30
Peptide concentration (log molar)
"- Peptide
FIG. 3. (a) Recognition of vaccinia-infected autologous targets by bulk lymphocyte culture from donor 032 (HLA-A*l/32
B*44/57). E:T ratio 50:1. Lysis of targets infected with control vaccinia (PB2-vac; 5.0%) subtracted, (b) Titration of peptide IS-
PRTLNAW. Effectors: peptide-specific line from donor 032, E:T 10:1. Lysis of targets pulsed with no peptide (1.8%) subtracted.
(c) Optimization of epitope KAFSPEVIPMF within 15-mer VVEEKAFSPEVIPMF. Effectors: peptide-specific line from donor
998, E:T 8:1. Lysis of targets pulsed with no peptide (6.1%) subtracted. Peptide concentrations all 1 pM.1696 GOULDER ET AL.
Table 3. Peptide Motif for HLA-B*5801a
and Consistency of Novel HLA-B*57-Restricted
epitopes with this motifb
HLA B5801 motifc
Position 2
S
T
A
W
F
HIV-1 HLA B57- and B5801-restricted epitopesd
Sequence Epitope
YH1QGYFPDWQ
GPGVRYPLTFGWCY
ISPRTLNAW
KAFSPEVIPMF
TSTLQEQIGW
QASQDVKNW
aSee Ref. 15.
bPreviously identified cross-restricted epitope YHTQGYF-
PDWQ11'12 and currently identified optimized epitopes shown.
Predicted anchor residues underlined.
cSee Ref. 17.
dAll except HTQGYFPDW described in this article.
eSeeRef. 11.
directed through non-HLA-B*57 class I molecules was a rela-
tively weak response to the HLA-A*2-restricted epitope
ILKEPVHGV1 (Fig. 4). In all seven HLA-B*57 or HLA-
B*5801 donors in the SP group tested, the dominant CTL re-
sponse was made through the HLA-B*57 or HLA-B*5801 mol-
ecule. In the single HLA-B*57-positive donor (196) in the
progressor group whose bulk CTLs were tested, there was no
recognition of Gag- or Pol-expressing HLA-B*57-matched tar-
gets, and the only peptide recognized by CTLs from this donor
was the HLA-B*35-restricted epitope, VPLRPMTY1 (not
shown).
DISCUSSION
A candidate HIV vaccine would ideally incorporate epitopes
that dominate CTL responses in SP donors. Importantly, these
epitopes would also need to be restricted by HLA class I mol-
ecules commonly found in ethnic groups where the prevalence
of HIV infection is high.
It is easy to identify which HLA class I molecules occur fre-
quently in areas of high HIV prevalence, but exceedingly dif-
ficult to demonstrate a significantly high frequency of any par-
ticular MHC class I in a group of LTNP donors because the p
value must be multiplied by the number of possible MHC class
I types and subtypes, of which there are well over 100. In this
case, we have examined a single class I molecule identified in
different studies6'7 as being more frequent than expected in an
SP group. Although the number of slow progressors and pro-
gressors in each group is fairly small, the observation that HLA-
B*57 is found at higher than expected frequencies in these three
independent studies is highly suggestive of an association of
HLA-B*57 with slow progression in HIV-1 infection.
Following the description of a "cross-restricted" HLA-B*57-
restricted CTL epitope within Nef that was equally presented
_ by HLA-B*58 targets,12 and the identification ofHLA-B*57 as
Position 9 a c'ass I molecule overrepresented in two SP groups,6,7 we
sought new HLA-B*57-restricted responses in a group of SP
donors and tested for cross-restriction in these responses. We
have identified five new HLA-B*57-restricted epitopes in SP
donors. One of these new epitopes is cross-restrictive, and in-
deed a dominant CTL response to the cross-restricted epitope
TSTLQEQIGW was identified in both HLA-B*57 donors and
an HLA-B*5801 donor.
The only difference in residues contributing to the binding
of peptides between HLA-B*57 and HLA-B*5801 is at position
45, within the B pocket, where a methionine in HLA-B*57 is
replaced by a threonine in HLA-B*58.19 This is a fairly minor
change, so it is not surprising that the anchor residues of pep-
tides binding to these two molecules appear to be the same.
Elution of peptides from C1R-B*5801 molecules revealed that
these anchors are serine, threonine, or alanine at position 2,
which would bind into the B pocket; and tryptophan or pheny-
lalanine at the C-terminal positions 9-11.15 All the peptide epi-
topes newly described here fit this motif, as does the cross-
restricted epitope previously described12 (Table 1).
The anchor residues for peptides binding to HLA-B*5802
may not be the same as for HLA-B*57 and HLA-B*5801, as
there are differences in the critical residues involved,19'20 and
effectors did not see HLA-B*5802 targets pulsed with the pep-
(Nef 115-125)e
(Nef 130-143)
(Gag 147-155)
(Gag 162-172)
(Gag 240-249)
(Gag 309-317)
•   .1
s? a |￡
(N W <
HLA A1/A2/B44 match
o h ￺
"5 >. H
HLA B57 match
FIG. 4. Immunodominance of HLA-B*57-restricted re-
sponses in donor 824 (HLA class I type: A*1/2 B*8/44).
Effectors: bulkcultured lymphocytes; E:T50:1. Targets: HLA-
AT/2 B*44-matched BCL targets pulsed with pools of 20-mers
spanning the Nef and Gag proteins and two described1 HLA-
A*2-restricted epitopes, SLYNTVATL and ILKEPVHGV.
HLA-B*57-matched targets (HLA class I type: A*24/31
B*27/57) pulsed with HLA-B*57-defined epitopes or putative
epitopes. Lysis of unpulsed targets subtracted (4.0% HLA-
A*l/2 B*44-matched targets; 7.0% HLA-B*57-matched tar-
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tide TSTLQEQIGW, when similarly pulsed HLA-B*57 and
HLA-B*5801 targets were seen. The probable explanation for
this is the presence of a tryptophan residue at position 97 in
HLA-B*5802, in place of an arginine at this position in HLA-
B*5801. This could affect binding in the F pocket as well as
the interaction with contact residues in the peptide.19-20
It is striking that the CTL responses of the donors are all
dominated by HLA-B*57- or HLA-B*5801-restricted responses
(for example, see Figs, la and 4). The reason for this is not
known. However, it may provide an additional clue to the ex-
planation for HIV-infected individuals with HLA-B*57 being
overrepresented in the SP group.
Finally, it is notable that the four epitopes described here
within Gag all are strongly conserved. In HIV-1 amino acid se-
quences listed in the Los Alamos database16 and in a study of
70 HIV-1 international isolates,21 there are no variants within
32 B clade strains listed for KAFSPEVIPMF, and one variant
only for TSTLQEQIGW (alanine for glycine at position 9) and
the ISPRTLNAW epitope (leucine for isoleucine in position 1).
QASQDVKNWis similarly conserved, but withrelatively com-
mon changes at position 5 of glutamate for aspartate. The
GPGVRYPLTFGWCY epitope within Nef is more variable,
conservative changes at positions 4 (isoleucine or threonine for
valine) and 6 (phenylalanine or tryptophan for tyrosine) being
seen in database sequences.
Conservation within database epitope sequences may mean
that escape mutation in these regions is constrained without
damaging the viability of the virus. This may in turn relate to
slow progression in HIV infection, as CTL responses directed
toward such regions may be more long-lasting. The conserva-
tion of these HLA-B*57-restricted epitope sequences supports
the evidence that they may represent qualitatively important
components of the immune response in slow progressor indi-
viduals in HIV infection.
ACKNOWLEDGMENTS
We thank the donors for their generous donations of blood;
our thanks also to Mary Brooks and the staff at the Oxford
Haemophilia Centre; Graham Taylor at St. Mary's Hospital,
London; and Simon Curtis and the staff at the Harrison Clinic,
Oxford for their help in the collection of blood samples. We
are also grateful to Gareth Plant, Sarah Garrard, and Gillian
Harcourt for help and discussion.
P.J.R.G is a Medical Research Council Special Training
Fellow.
REFERENCES
1. McMichael AJ and Walker BD: CTL epitopes: Implications for
AIDS vaccines. AIDS 1994;8:S155-S173.
2. Koup RA, Safrit JT, Cao Y, Andrew CA, McLeod G, Borkowsky
W, Farthing C, and Ho DD: Temporal association of cellular im-
mune responses with the initial control of viraemia in primary hu-
man immunodeficiency virus type 1 syndrome. J Virol
1994;68(7):4650-4655.
3. Carmichael A, Jin X, Sissons P, and Borysiewicz L: Quantitative
analysis of the human immunodeficiency virus type 1 (HTV-1)-
specific cytotoxic T lymphocyte (CTL) response at different stages
of HTV-1 infection: Differential responses to HTV-1 and
Epstein-Barr virus in late disease. J Exp Med 1993;177(2):249-256.
4. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR,
Bende RJ, Keet IP, Eeftinck-Shattenkerk JK, Osterhaus AD,
Shuitemaker H, and Miedama F: Kinetics ofGag-specific cytotoxic
T lymphocyte responses during the clinical course of HIV-1 in-
fection: A longitudinal analysis ofrapid progressors and long-term
asymptomatics. J Exp Med 1995;181:1365-1372.
5. Imanishi T, Akaza T, Kimura A, Tokunaga K, and Gojobori T:
Al￭ele and haplotype frequencies for HLA and complement loci in
various ethnic groups. In: HLA 1991—Proceedings ofthe Eleventh
International Histocompatibility Workshop and Conference (Tsuji
K, Aizawa M, and Sasazuki T, Eds.), Vol. 1. Oxford University
Press, 1992, pp. 1065-1220.
5a. Krausa P, McAdam S, Bunce M, Whitworth J, Biryahwaho B, French
N, Tugume B, Gilks C, and Gotch F: HLA-A, -B, -C, -DRB3,
-DRB4, -DRB5 and -DQB1 polymorphism detected by PCR in a semi-
urban HIV-positive Ugandan population. Submitted for publication.
6. Klein MR and Miedama F: Long-term survivors of HIV infection.
Trends Microbiol 1995;3(10):386-391.
7. Kaslow RA, Carrington M, Apple R, Munoz A, Saah AJ, Goedert
JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels C, Blattner W, Phair
J, Erlich H, and Mann DL: Influence of combinations of major his-
tocompatibility complex genes on the course of HIV-1 infection.
Nature Med 1996;2(4):405^111.
8. Hill AVS: HIV and HLA: Confusion or complexity? Nature Med
1996;2(4):395-396.
9. Bunce M, Barnardo M, Procter J, Marsh S, Vilches C, and Welsh
KI: High resolution HLA-C typing by PCR-SSP: Identification of
allelic frequencies and linkage disequilibrium in 604 consecutive
unrelated random UK Caucasians and a comparison with serology.
Tissue Antigens 1996 (in press).
10. Bozon MV, Delgado JC, Turbay D, Salazar M, Granja CB, Alosco
SM, Dupont B, and Yunis EJ: Comparison of HLA-A antigen typ-
ing by serology with two polymerase chain reaction-based DNA
typing methods: Implications for proficiency testing. Tissue
Antigens 1996;47(6):512-518.
11. Culmann B, Gomard E, Kieny M-P, Guy B, Dreyfus F, Saimot
A-G, Sereni D, Sicard D, and Levy J-P: Six epitopes reacting with
human cytotoxic CD8+ T cells in the central region of the HIV-1
Nef protein. J Immunol 1991;146:1560-1565.
12. Culmann B, Gomard E, Kieny M-P, Guy B, Dreyfus F, Saimot
A-G, Sereni D, Sicard D, and Levy J-P: An antigenic peptide of
the HIV-1 Nef protein recognised by cytotoxic T lymphocytes of
seropositive individuals in association with different HLA-B mol-
ecules. Eur J Immunol 1989;19:2382-2386.
13. Bunce M, Fanning GC, and Welsh KI: Comprehensive, serologi-
cally equivalent DNA typing for HLA-B by PCR using sequence-
specific primers (PCR-SSP). Tissue Antigens 1995;45:81-90.
14. Bunce M, O'Neill CM, Barnardo CNM, Krausa P, Browning MB,
Morris PJ, and Welsh KI: Phototyping: Comprehensive DNA typ-
ing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by
PCR with 144 primer mixes utilising sequence-specific primers
(PCR-SSP). Tissue Antigens 1995;46(5):355-367.
15. Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung
G, and Rammansee H-G: Peptide motifs of HLA-B58, B60, B61
and B62 molecules. Immunogenetics 1995;41:165-168.
16. Myers G, Hahn BH, Mellors JW, Henderson LE, Korber B, Jeang
K-T, McCuthchan FE, and Pavlakis GN (Eds.): Human
Retroviruses and AIDS 1995: A Compilation and Analysis of
Nucleic Acid and Amino Acid Sequences. Los Alamos National
Laboratory, Los Alamos, New Mexico, 1995.
17. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, and
McMichael A: HTV-1 gag-specific cytotoxic T lymphocytes de-
fined with recombinant vaccinia virus and synthetic peptides.
Nature (London) 1988;336:484-^t87.1698 GOULDER ET AL.
21. Louwagie J, McCutchan FE, Peeters M, Brennan TP, Sanders-Buell
E, Eddy GA, van der Groen G, Fransen K, Gershy-Damet G-M,
Deleys R, and Burke DS: Phylogenetic analysis of gag genes from
70 international HTV-1 isolates provides evidence for multiple
genotypes. AIDS 1993;7:769-780.
18. Johnson RP, Trocha A, Yang L, Mazzara G, Panicali P, Buchanan
P, and Walker BD: HTV-1 gag-specific cytotoxic T lymphocytes
recognise multiple highly conserved epitopes. Fine specificity of
the gag-specific response is defined by using unstimulated periph-
eral blood mononuclear cells and cloned effector cells. J Immunol
1991;147(5):1512-1521.
19. Arnett KL and Parham P: HLA class I nucleotide sequences. Tissue
Antigens 1995;46:217-257.
20. Madden DR, Garboczi DN, and Wiley DC: The antigenic identity
of peptide-MHC complexes: A comparison of the conformations
offive viral peptides presented by HLA-A2. Cell 1993;75:693-708.
Address reprint requests to:
Philip Goulder
Molecular Immunology Group
John Radcliffe Hospital
Headington, Oxford OX3 9DU, United Kingdom